medigraphic.com

2017, Number 1

<< Back

Rev Med Inst Mex Seguro Soc 2017; 55 (1)

Down syndrome and heart block secondary to neonatal lupus

Illana-Bravo CL, Méndez-Martínez S, Juan-Martínez ME

Language: Spanish
References: 24
Page: 128-132
PDF size: 703.06 Kb.


ABSTRACT

In Down syndrome, so far, has not been reported it’s association with congenital heart block, this entity is rare and occurred in only 1% of mothers who have systemic lupus erythematosus, the presence of anti-Ro antibodies cross the placenta presenting neonatal lupus with skin lesions and congenital heart block, bradycardia, which is why we describe the following case.
This is a new male end product of asymptomatic young mother, but serological birth with stigmata of Down syndrome, birth presents congenital bradycardia rare manifestation abnormalities, but common in children of mothers with lupus are initiated study protocol, realizing you including laboratory tests and immunological studies cabinet as electrocardiogram and echocardiogram, which gave tone to take the mother immunological studies, being positive antiRo.
We concluded that the risk of heart block in a patient with Down syndrome is the same as for the general population.


REFERENCES

  1. Aguilera PP, Vicente VA, González-EA. Lupus eritematoso neonatal. Seminarios de la Fundación Española de Reumatología. 2011;12(1):15-20.

  2. orcel CR, Tapia CL, Díaz CR, Gutiérrez PMT. Neonatal lupus erythematosis: A five-year case review. Reumatol Clin. 2014;10(3):170-3.

  3. Isayama T, Inamura N, Shiono N. Neonatal lupus erythematosus complicated by improved congenital complete heart block. Official Journal of the Japan Pediatric Society. 2013;2:521-3.

  4. Yang C, Shih IH, Yang CH. Neonatal lupus erythematous infants and their mother: A 10-year retrospective study. Dermatologica Sinica. 2010;28:107-12.

  5. Amoura Z, Arnaud L, Mathian A. Neonatal lupus: a fetal- maternal immunisation model? Bull Acad Natl Med. 2012;196(8):1625-37.

  6. Yildirim A, Tunaodlu SF, Karaadac TA. Neonatal Congenital Heart Block. Indian Pediatrics. 2013;50(16):483-8.

  7. Reed HJ, Clancy RM, Lee HK, Saxena A, Izmirly MP, Buyon PJ. Umbilical cord blood levels of maternal antibodies reactive with p200 and full-length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus. Arthritis Care and Research. 2012;64(9):1373-81.

  8. Rozenblyum EV, Sukhdeo S, Jaeggi E, Hornberger L, Wyatt P, Laskin CA, Silverman ED. A42: anti-Ro and anti-La antibodies in the general pregnant population: Rates and fetal outcomes. Arthritis Rheumatol. 2014;66(11):63.

  9. Roy KK, Subbaiah M, Kumar S, Sharma JB, Singh N. Feto-maternal outcome in pregnancies complicated by isolated fetal congenital complete heart block. J Obstet Gynaecol. 2014;15:1-3.

  10. Ambrosi A, Wahren-Herlenius M. Congenital heart block: Evidence for a pathogenic role of maternal autoantibodies. Arthritis Research and Therapy. 2012;14:208.

  11. Ambrosi A, Sonesson SE, Wahren-Herlenius M. Molecular mechanisms of congenital heart block. Exp Cell Res. 2014;325(1):2-9.

  12. Suthar R, Sahu JK, Rohit M, Khandelwal NK, Singhi P. Stroke in a case of neonatal lupus: An uncommon complication. J Child Neurol. 2014;21:157-60.

  13. Yahalom M, Roguin N, Antonelli D, Suleiman K, Turgeman Y. Association of heart block with uncommon disease States. Int J Angiol. 2013;22(3):171-6.

  14. Brucato A. Prevention of congenital heart block in children of SSA-positive mothers. Rheumatology. 2008;47:35-7.

  15. Makino S, Yonemoto H, Itoh S, Takeda S. Effect of steroid administration and plasmapheresis to prevent fetal congenital heart block in patients with systemic lupus erythematosus and/or Sjögren’s syndrome. Acta Obstet Gynecol Scand. 2007;86(9):1145-6.

  16. Routsias JG, Kyriakidis NC, Friedman DM, Llanos C, Clancy R, Moutsopoulos HM et al. Association of the idiotype: Antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block. Arthritis Rheum. 2011;63(9):2783-9.

  17. Friedman DM, Llanos C, Izmirly PM, Brock B, Byron J et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum. 2010;62(4):1138-46.

  18. Pisoni CN, Brucato A, Ruffatti A, Espinosa G, Cervera R, Belmonte-Serrano M et al. Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. Arthritis Rheum. 2010;62(4):1147-52.

  19. Di Mauro A, Caroli CV, Favia GG, Calderoni G, Cicinelli E, Laforgia N. Antenatal and postnatal combined therapy for autoantibody-related congenital atrioventricular block. BMC Pregnancy Childbirth. 2013;13:220.

  20. Shepard CW, Kochilas L, Vinocur JM, Bryant R, Harvey BA, Bradley S et al. Surgical placement of permanent epicardial pacing systems in very low-birth weight premature neonates: A review of data from the Pediatric Cardiac Care Consortium (PCCC). World J Pediatr Congenit Heart Surg. 2012;3(4):454-8.

  21. Haydin S, Ozturk E, Ergul Y, Tuzcu V. Intrathoracic implantation of a dual-chamber pacemaker in a preterm infant with congenital AV block. J Card Surg. 2013;28(2):196-8.

  22. Villain E. Indications for pacing in patients with congenital heart disease. Pacing Clin Electrophysiol. 2008;31(1):17-20.

  23. Gregoratos G, Abrams J, Epstein AE et al. ACC/ AHA/NASPE 2002 Guideline update for implantation of cardiac pacemarkers and antiarrhythmia davices summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2002;40(9):1703-19.

  24. Mitra S, Saha AK, Sardar SK, Singh AK. Remission of congenital complete heart block without anti-Ro/ La antibodies: A case report. Ann Pediatr Cardiol. 2013;6(2):182.




2020     |     www.medigraphic.com